- 1 -

CURRICULUM VITAE ALISON L JONES MD FRCP July 2004

- 2 -

NAME: Alison Louise Jones DATE OF BIRTH: 30 August 1957 NATIONALITY: British GMC No: 2628246 EDUCATION Cheltenham Ladies' College 1970 - 1975 Bristol University Medical School 1975 - 1980 QUALIFICATIONS MB ChB Bristol University 1980 MRCP (UK) Royal College Physicians 1983 JCHMT Accreditation Medical 1992

Oncology MD Bristol University 1993 FRCP Royal College Physicians 1998 CURRENT APPOINTMENT Sept 1993 → Consultant Medical Oncologist and Honorary Senior Lecturer, Royal Free Hospital, London, Hampstead, NW3 2QG

Honorary Consultant, Whittington Hospital, London, N19 June 02 → Clinical Director, Cancer Services: UCLH Consultant Medical Oncologist, UCLH

- 3 -

CLINICAL AND SERVICE ACTIVITY I was appointed as a consultant at the Royal Free in 1993 with clinical responsibility for breast, lymphoma, lung, melanoma and renal cancer. In line with my clinical interests and national government directives on the improvement of cancer care and local service development we have now increased the number of consultants in the department so I am able to specialise in my primary interest which is breast cancer. I attend 3 breast multidisciplinary teams per week and 3 NHS breast clinics. I am in the process of setting up an additional clinic for women with genetic breast cancer in conjunction with a colleague in clinical genetics. I run a research based practice, in terms of clinical trials and translational activity I have particular clinical interest in young women with breast cancer and issues relating to fertility, pregnancy, communication and menopause and I advise support organisations, such as Breast Cancer Care and Cancer BACUP on these and other breast cancer related issues and am part of a BASO group developing guidelines for pregnancy associated breast cancer. Breast Tumour Board I am chair of the breast tumour board within the North London Cancer Network which has a constituency of 6 separate breast cancer units. We have developed agreed published guidelines for the management of cancer within the network, including referral, treatment and follow up pathways for all aspects of breast disease. In addition we have standardised patient information leaflets across the network. We have facilitated equity of access to service, algorithms of drug usage and agreed prescribing and research activity and maintain an active trial portfolio across the network. The Breast Tumour Board is an active multidisciplinary group which meets every 2 months and has a joint meeting with the neighbouring network in Mount Vernon as an Awayday once a year. Ongoing projects include evaluation of access to support groups for patients and development of services for sentinel node biopsy according to BASO guidelines. These guidelines are being adopted by other networks. EDUCATION I take part in the teaching of undergraduates as part of my role as a Senior Lecturer in a University Teaching Hospital. My main interest however is in postgraduate education as follows;

1. London Course – this is a compulsory day release course for year 1 and 2 trainees in medical and clinical oncology at SpR level and is recognised by both colleges as the standard for implementation of higher training and serves as the basis for the curriculum of FRCR part 1.

2. I was co-organiser of a summer school which was an advanced practice course for trainees in years 3 and 4 of training between 1996 and 1999.

3. Deanery activity – I have been the first chair of the PAN-London specialist training committee for medical oncology since its inception and have a committee with 5 programme directors supervising approximately 70 trainees holding NTN’s or LAT appointments within the Thames region. We have developed the programmes and facilitated trainee’s entry into research and coordinated appraisal, RITA and advice to individual trainees as well as prioritising development of new posts. I have developed reciprocal links with the PAN-London Committee for Clinical Oncology in the interests of joint training.

4. Royal College – have served on the Joint Council for Clinical Oncology with the remit to advise on education in light of my role in co-ordinating the London

- 4 -

Course and continue to serve as Regional Specialty Adviser for Medical Oncology advising on new posts within the region and providing advice to doctors seeking a career in medical oncology. I regularly assess training programmes across the UK in my role in the SAC.

I have continued my own postgraduate education with regular participation in local, national and international meetings and attended appropriate courses including communication skills, interview, appraisal, equal opportunities. I have also attended courses on mentoring. I have contributed to development of interactive case presentations in breast cancer for postgraduate teaching. My interest in education has developed with a research interest and I am now co-supervisor of a CR UK fellow who is evaluating the educational needs for medical students in their transition to junior doctors. MANAGERIAL 1. Royal Free Hospital. With the implementation of Calman Hine I was appointed as lead clinician within the Royal Free for 3 years advising on cancer related issues within the trust and liaising with the health authority. This was important at the time of development of cancer networks and involved close liaison with the network and trust in terms of service development. I have facilitated the first peer review process within the trust and also a CHI visit with respect to breast services. I have facilitated the development of multidisciplinary team working and tumour operational groups and cross-site working with colleagues in the joint cancer centre at UCLH. 2. UCLH. In 2002, I was appointed Clinical Director of Cancer Services at UCLH with responsibility for a large directorate of haemato-oncology. This has been extended to involve adolescent oncology. This has been an opportunity to be involved in the transfer of services into a new hospital site and the development of an ambulatory care facility. I have set up a clinical trials facilitation committee and am instrumental in developing new consultant posts, co-ordinated site-specific care and annual governance reports and appraisal and job planning. 3. Joint Cancer Centre. I am joint chair of the supervisory group for the Joint Cancer Centre which oversees the implementation groups for head and neck, pancreatico-biliary and upper gastro-intestinal cancer in light of transfer of services across the joint cancer centre. I am also on the joint cancer and peer review working group and the joint cancer and outreach development group which is looking at the development of link clinical nursing and service areas across the North London Cancer Network. In addition I set up the diagnostic board for the NLCN in 2002. AUDIT I liaise closely with the Audit Department to facilitate the accurate data collection within Oncology required by the Health Authority and supervise a member of the Audit Department. Within the Royal Free I have developed systematic continuing audit of protocol-driven care based on our protocol book in association with pharmacy and

- 5 -

nursing colleagues. I am a member of the Advisory Board for the Thames Breast Cancer Audit and am also a member of the Thames Cancer Registry Purchasers' Advisory Board. RESEARCH Clinical I am active in clinical research in breast cancer and maintain a portfolio of clinical trials in the context of national research bodies such as the NCRN and also with novel agents through the pharmaceutical industry. I have been on the national steering groups for several trials including: MRC AB01 (metastatic) Angloceltic I and 2

TACT (adjuvant) Neo TANGO (neoadjuvant) OPTION (ovarian protection during chemotherapy) Breakthrough (genetic breast cancer)

I am invited speaker and/or chair at many national and international meetings on subjects related to aspects of breast cancer care. From 1999 until 2004, I was a member of the CIRB (Central Institutional Review Board) for the Cancer Research Campaign which is the Ethics and Evaluation Committee for evaluating phase I and 2 studies sponsored and developed by the CRC. Psychosocial I was a member of the Research Steering Group for Cancer BACUP from 1998 – 2002. Our remit was to develop research questions to integrate the Cancer BACUP database and to systematically evaluate the counselling service and to develop further research questions relating to the information and support needs of patients with cancer. We obtained funding from CRUK for a studentship and support for this work which has resulted in a number of publications including a research report into the information preferences of people with cancer published in October 2001. I also served as a member of the CRC Educational / Psychosocial Research Committee until 1993 which involved evaluation and awarding of grants and following progress of studentships. I still sit on the Fellowship Award Committee for this Committee under CRUK. At the Royal Free, I have been involved with the Department of Family Health in evaluation and communication between families when cancer is diagnosed. This work has led to publications and a change of practice with appointment of a support team for oncology patients with cancer who have children. I am on the steering committee of Continuity of Care Study, funded by the Department of Health, which is looking at the issues involved at transition points across the cancer journey for patients with different tumour types within 3 networks. I am also involved with a project looking at coping mechanisms for patients with cancer within the Royal Free. Laboratory My MD was a laboratory-based project evaluating the role of cytokines in relation to chemotherapy in terms of enhancing chemotherapy effect in melanoma and protection of chemotherapy side effects. I supervised an MS student in a project looking at HER-2 in breast cancer and

- 6 -

evaluation of immuno-histochemical methods. I had a collaborative project within the department of haematology supervising a PhD student (Pani Theocharous, PhD completed) looking at a novel immuno-cytochemical assay to detect and keratinise epithelial tumour cells in the peripheral blood of patients with cancer, in particular breast cancer and to evaluate the importance of these cells as prognostic and predictive factors in relation to treatment. I am principal study investigator on a project with Department of Health funding evaluating the pharmaco-genomics of anthracycline mediated cardio-toxicity, which is an important area for the long term safety and health of women who have received adjuvant treatment for breast cancer (principal investigator Professor H. Montgomery). STUDENTSHIPS AND GRANTS 1. Rebecca Watson MSc. 2. Pani Theocharous Immuno-histochemical detection of epithelial cells in bone marrow. 3. Jude Gaffan. CR UK Fellowship. I am co-supervisor for Dr Jude Gaffan who has recently obtained a CR UK Fellowship for a project ‘The Needs and Understandings of Medical Students in Relation to Cancer During their Transition from Medical Student to Pre-Registration House Officers’. 1. Continuity of Care Study (NHS service delivery organisation). 2. Communication with primary care, North London Workforce Development Confederation (this was a 2 year project to develop a pool to facilitate communication between primary and secondary care in relation to patients with cancer thereby improving referral and follow up pathways. This has been done in conjunction with the Medic-to-Medic project and has been completed for 5 cancer types and is being piloted with local primary care. 3. Peri-menopausal bone loss, Grant holder Novartis. 4. Pharmaco-genomics of anthracycline mediated cardio-toxicity, Department of Health grant. I am a regular reviewer on grant applications for Breast Cancer Care and CRUK (psychosocial studentships) ADVISORY BOARDS CURRENT ADVISORY BOARDS PREVIOUS ADVISORY BOARDS Astra Zeneca BMS Aventis Pharma Abbot Lab BMS (Breast Baker Norton Faslodex (International Speakers Bureau) Datamonitor Medical Experts Panel Johnson & Johnson Hycamtin Lilly Independent Review Panel Novartis Lewin Group Pfizer (voriconazole) North Thames Cancer Waiting Times Pierre Fabre Roche Oncology Speaker Bureau ROCHE (Herceptin / Xeloda) Shirehall Stratagen The Medicine Group Topotecan

CHARITIES I am a medical adviser for Europa Donna, the European patient advocacy group for breast cancer and regularly lecture for them. I also provide regular advice and

- 7 -

participate in national and local meetings through lectures and workshops for breast cancer care. I am a specialist adviser for Cancer BACUP. At a local level I am an adviser to the Cancer Counselling Trust and a medical adviser to Cancerkin, a hospital based support group for women with breast cancer. I am a trustee for the Marc Fisher Trust a charity sponsoring research into lymphoma, set up in memory of a patient. PREVIOUS APPOINTMENTS Aug 1980 - Feb 1981 House Physician, Gloucester Royal Infirmary

Dr S Wilkinson Feb 1981 - Aug 1981 House Surgeon, Princess Margaret Hospital, Swindon

Mr P Huddy Aug 1981 - Aug 1982 Senior House Officer, General, Chest and Gastrointestinal

Medicine and Rheumatology Good Hope General Hospital, Sutton Coldfield

Professor B H Bass & Dr P Hillenbrand Aug 1982 - Aug 1983 Senior House Officer, General Medicine and Clinical

Haematology, East Birmingham Hospital Dr M Leyland

Aug 1983 - Aug 1984 Registrar, General Medicine, Hackney Hospital, London

Dr M Clark & Dr P Kumar Aug 1984 - Aug 1985 Registrar Medical Oncology & Palliative Medicine, Royal

Marsden Hospital, Fulham Road, London Dr E Wiltshaw & Dr G Hanks

Aug 1985 - Aug 1986 Registrar in Clinical Haematology, St Bartholomew's

Hospital, London Professor A Waters & Dr J Amess

Aug 1986 - Aug 1988 Clinical Research Fellow and Honorary Registrar, Institute

of Cancer Research and Royal Marsden Hospital, Sutton Dr J Millar Aug 1988 - July 1992 Senior Registrar and Lecturer in Medicine, Royal Marsden Hospital and Institute of Cancer Research, London and Surrey July 1992 - Sept 1993 Locum Consultant Medical Oncologist, Royal Marsden

Hospital, Fulham Road, London LEARNED SOCIETIES Royal College of Physicians: SAC in Medical Oncology 1998 → Regional Advisor, Medical Oncology 1996 →

- 8 -

Joint Collegiate Council for Oncology: 1993 - 1996 1995 - 1999 Education Sub-Committee 1999 →

London Course 1999 - 2004 London Deanery: Chair: STC in Medical Oncology 1996 → Thames Cancer Registry: Chair: Prospective Breast Audit Panel 2002 → Cancer Research Campaign: Institutional Review Board (Ethics) 1998 - 2003 Education/Psychosocial Committee 1999 - 2002 North London Cancer Network: Chair: Breast Tumour Board 1999 → Member: Diagnostics Board : Chemotherapy Board British Breast Group (member) 1995 → European Society for Medical Oncology (member) American Society of Clinical Oncology (member) Anglo-Celtic Research Group (UK) Europa Donna Advisory Board ACADEMIC/RESEARCH APPOINTMENTS Cancer Research Campaign Phase I/II Committee 1993-1996 Cancer Research Campaign Breast Cancer Trials Group 1993-1997

New Studies Working Group 1993-1997 UKCCCR British Cancer Trials Group 1994-

Melanoma Working Party 1994-1997 BACUP Research Advisory Board 1996- Cancer Research Campaign Education & Psychosocial 1997-2002

Research Committee Cancer Research Campaign Central Institutional Review Brd 1998-2003 CRUK / UCL Scientific Advisory Committee 2001-

- 9 -

EDITORIAL BOARDS Current Opinion in Oncology: Bibliographic Support Editor 1992- Anti Cancer Drugs 1994- Clinical Oncology 1994-1998 Opinion - Key Reviews in Oncology 1996- Regular reviewer for: British Journal of Cancer; Annals of Oncology; Cancer, Chemotherapy and Therapeutics; Lancet Oncology; British Medical Journal. REGIONAL ACTIVITY Member North Thames Medical Training Committee 1995- Chair Pan Thames Specialty Training Committee 1996-

in Medical Oncology Member Thames Cancer Registry Purchasers 1997-2003

Advisory Group NATIONAL ACTIVITY Association Cancer Physicians:

Committee Member 1991-1993 Education Subcommittee 1992-

Royal Society of Medicine: Member of Council 1996-1999 Royal College of Physicians:

College Committee Oncology 1993-1999 Regional Advisor Medical Oncology 1996- Representative on Education Board 1996- of Royal College of Radiologists 1997- Standing Advisory Committee - Med Onc 1998- Joint Council for Clinical Oncology Committee Member 1993-1995: 1996-1999 Joint Education Subcommittee on Core 1999- Training

- 10 -

PUBLICATIONS MD THESIS Jones AL Modulation of the therapeutic index of chemotherapy and radiotherapy by cytotoxic drugs and biological agents. Bristol University 1993 PAPERS 1 Amos TJ, Kirk B, Amess JAL, Jones AL, Hinds CT.

Bone marrow hypoplasia during intensive care: bone marrow culture studies implicating ranitidine in the suppression of haemopoiesis. Human Toxicol 1987; 6: 503-506.

2 Selby P, Hobbs S, Viner C, Jackson E, Jones AL, Newell D, Calvert AH,

McElwain T, Fearon K, Humphreys J, Shiga T. Tumour necrosis factor in man: clinical and biological observations. Br J Cancer 1987; 56: 803-808.

3 Millar BC, Millar JL, Jones AL, Feary SW, Robertson D, Bell JBG.

Activation of murine 'T' lymphomas in the presence of a human myeloma cell line, RPM-8226, in vivo. Br J Cancer 1988; 57: 290-292.

4 Jones AL.

Mitoxantrone used as a single agent in advanced breast cancer. In: Proceedings of the 2nd Nordic Novantrone Symposium 1988; 7-12.

5 Milliken S, Powles R, Jones AL, Helenglass G.

Pharmacokinetics of oral fluconazole in autologous bone marrow transplantation recipients given TBI and high dose melphalan. Transplantation Proc 1989; 21: 3067.

6 Jones AL, Selby P.

Clinical applications of tumour necrosis factor. Progress in Growth Factor Res 1989; 4: 131-137.

7 Jones AL, Millar JL.

Growth factors in haemopoiesis. Current Med Lit 1989; 4: 131-137.

8 Powles TJ, Jones AL, Ashley SE, Tidy A.

Menstrual influence on surgical cure of breast cancer. Lancet 1989; ii: 1343-1344.

- 11 -

9 Jones AL, Selby P, Viner C, Hobbs S, Gore ME, McElwain TJ.

Hypothesis: tumour necrosis factor, cholestatic jaundice and chronic liver disease. Gut 1990; 31: 938-939.

10 Jones AL, Williams MP, Powles TJ, Oliff JFC, Hardy JR, Cherryman G,

Husband J. Magnetic resonance imaging in the detection of skeletal metastases in patients with breast cancer. Br J Cancer 1990; 62: 296-298.

11 Jones AL, Selby P.

Tumour necrosis factor; clinical relevance. Cancer Surveys 1990; 8: 817-836.

12 Hardy J, Jones AL, Gore ME, Viner C, Selby P, Wiltshaw E.

Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor. Eur J Cancer 1990; 26: 771.

13 Powles TJ, Tillyer CJ, Jones AL, Ashley SE, Treleaven J, Davey JB, McKinna

JA. Prevention of breast cancer using tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990; 26: 680-684.

14 Jones AL, Cunningham DC.

Ondansetron. Taking the sickness out of cancer therapy. Prescriber 1990, pp 17-20.

15 Jones AL, Dowsett MJ, Powles TJ, Gallagher CJ, Coombes RC.

Treatment of advanced breast cancer with miconazole: a potential inhibitor of peripheral oestrogen synthesis. Eur J Cancer 1990; 3: 301.

16 Jones AL, Millar JL, Millar BC, Powell B, Selby P, Winkley A, Lakhani S, Gore

ME, McElwain TJ. Enhanced antitumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo. Br J Cancer 1990; 62: 776-781.

17 Jones AL, Forgeson GV, Powles TJ, Coombes RC.

A clinical study of nafazatron in advanced breast cancer. Cancer Chemotherapy Pharmacol 1991; 27: 326-329.

- 12 -

18 Jones AL, Hardy JR, Newell DR, Smith IE.

Clinical study and pharmacokinetics of lonidamine in advanced non-small cell lung cancer. Eur J Cancer 1991; 4: 519.

19 Powles TJ, Trott PA, Cherryman G, Clarke S, Ashley S, Coombes RC, Jones

AL, Sinnett HD, Nash AG. Fine needle aspiration cytodiagnosis as a prerequisite for primary medical treatment of breast cancer. Cytopathology 1991; 2: 7-12.

20 Jones AL.

Tumour necrosis factor. Transfusion Science 1991; 12: 67-73.

21 Lonning PE, Jacobs S, Jones AL, Haynes B, Powles TJ, Dowsett M.

The influence of CGS16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991; 63: 789-793.

22 Haynes BP, Jarman M, Dowsett M, Mehta A, Lonning P, Grigg LJ, Jones AL,

Powles T, Coombes RC. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2, 6,-dione in postmenopausal breast cancer patients. Cancer Chemotherapy Pharmacol 1991; 27: 367-372.

23 Jones AL, Holborn J, Ashley S, Smith IE.

Effective new low toxicity chemotherapy with carboplatin, vinblastine, methotrexate (CVM) for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide. Eur J Cancer 1991; 27: 866-870

24 Jones AL, Powles TJ.

Tamoxifen in the management of breast disease. Mat & Child Health 1991; 16:116-120.

25 Jones AL, Selby PJ.

Biological therapy. Radiotherapy & Oncology 1991; 20: 211-223.

26 Jones AL, Spyrou N, Rowley M, Powles TJ.

Ranitidine induced thrombocytopenia and pancytopenia in patients on prophylactic ranitidine. Eur J Internal Medicine 1991; 2: 183-185.

- 13 -

27 Powles TJ, Jones AL, Judson IR, Hardy JR, Sinnett HD, Ashley SE.

Low toxicity combination cytotoxic chemotherapy of advanced breast cancer using mitomycin C, mitoxantrone and methotrexate (3M) or vincristine, anthracycline and cyclophosphamide (VAC). Br J Cancer 1991; 64: 406-411.

28 Jones AL, Powles TJ.

Antiosteolytic treatments for skeletal metastases: general principles and clinical results. (Eds: RGG Russell & JA Kanis). Royal Society of Medicine Symposium 1991, no 176, p 71-82.

29 Jones AL, Powles TJ.

Chemoprevention of breast cancer with tamoxifen. Chemoimmunoprevention of Cancer. Eds: Pastorio U & Hong WK. Thieme Medical Publishers Inc., New York, 1991, pp 225-229

30 Jones AL, Cunningham DC. The management of vomiting associated with cytotoxic therapy. Br J Hospital Medicine 1991; 45: 85-89.

31 Jones AL.

Inhibition of peripheral aromatisation by 4-hydroxyandrostenedione: radio-isotope tracer studies in vivo. In: 4-hydroxyandrostenedione - a new approach to hormone dependent cancer. Eds: RC Coombes, M Dowsett), RSM, 1991, pp 29-33.

32 Jones AL.

Chemotherapy for advanced breast cancer: is there a current best regimen? Cancer Topics 1991; 8: 54-58.

33 Jones AL, Hill AS, Soukop M, Hutcheon AW, Cassidy J, Kaye SB, Sikora K,

Carney DN, Cunningham D. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338: 483-487.

34 Jones AL, McNeill F, Jacobs S, Lonning PE, Dowsett M, Powles TJ.

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992; 28: 1712-1716

35 Jones AL.

Cancer: what steps can we take to prevent it? MIMS 1991; 18: 48-56.

- 14 -

36 Jones AL, Powles TJ.

Prevention of breast cancer. Current Opinions in Oncology 1991; 3: 1024-1028.

37 Jones AL, O'Brien MER, Lorentzos A, Viner C, Moore J, Gore ME.

A randomised phase II study of carmustine (BCNU) alone or in combination with tumour necrosis factor in patients with advanced melanoma. Cancer Chemotherapy Pharmacol 1992; 30: 75-76

38 Jones AL, Cropley I, O'Brien MER, Lorentzos A, Moore J, Jameson B, Gore

ME. Infectious complications of subcutaneous interleukin-2 and interferon alpha. Lancet 1992; ii

39 Dowsett M, MacNeill F, Mehta A, Newton C, Haynes B, Jones AL, Jarman M,

Lonning P, Powles TJ, Coombes RC. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2, 6-dione ("pyridoglutethimide") in postmenopausal breast cancer patients. Br J Cancer 1991; 64: 887-894.

40 Jones AL.

Hormonal treatment of breast cancer. Therapy Express 1992; 59:1-4

41 Lonning PE, Dowsett M, Jones AL, Ekse D, Jacobs S, McNeil F,

Johannessen DC, Powles TJ. Aminoglutethimide may further enhance oestrogen suppression and cause tumour regression in breast cancer patients resistant to treatment with the aromatase inhibitor 4-hydroxyandrostenedione. Breast Cancer Res Treat 1991; 23: 57-62

42 Iveson T, Ramage FR, Walsh G, Jones AL, Smith IE.

Preliminary report on continuous infusional 5-fluorouracil with epirubicin and cisplatin in the treatment of locally advanced metastatic breast cancer. J Infusional Chemotherapy 1992; 3, 1 19- 21

43 Jones AL, Lee GJ, Bosanquet N.

The cost-effective use of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. Eur J Cancer 1992; 29a: 51-56

44 McNeill FA, Jones AL, Jacobs S, Lonning PE, Powles TJ, Dowsett M.

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992; 66: 692-697

- 15 -

45 Jones AL, Powles TJ, Law M, Tidy A, Easton D, Coombes RC, Smith IE,

McKinna JA, Nash A, Ford HT, Gazet J-C. Controlled trial of adjuvant aminoglutethimide in operable breast cancer: analysis at 8 years follow-up. J Clin Oncol 1992; 10: 1547-1552

46 Jones AL, Powles TJ, Treleaven J, Burman JF, Nicolson MC, Chung H-I,

Ashley SE. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer 1992; 66: 744-747

47 Watkinson AF, A'Hern RP, Jones AL, King DM, Moskovic E.

The role of percutaneous nephrectomy in malignant urinary tract obstruction. Clin Rad 1992; 47: 32-35

48 Svensson WE, Tohno E, Cosgrove DO, Al Muvani B, Powles T, Jones AL.

Effects of needle aspirate on the ultrasound appearance of the breast: a guide to the proper timing of the ultrasound examination. Radiology 1992; 185: 709-713

49 Jacobs S, MacNeill F, Lonning P, Dowsett M, Jones AL, Powles TJ.

Aromatase activity, serum oestradiol and their correlation with demographic indices. J Steroid Biochem Mol Biol 1992; 41: 769-771

50 Smith IE, Jones AL, O'Brien MER, McKinna JA, Sacks N, Baum M. Primary medical (neoadjuvant) chemotherapy for operable breast cancer. Eur J Cancer 1993; 29A: 592-595

51 Jones AL.

Recent developments in the diagnosis and management of breast cancer. Medical Monitor 1993; 58-62

52 Jones AL, Powles TJ.

Breast Cancer Chemoprevention. Current Practice in Surgery 1993; 5: 162-165

53 Jones AL, Holborn J, Ashley S, Smith IE.

CVM versus ACE in the treatment of small cell lung cancer. Oncology 1993; 50: 10-15

54 Jones AL, Smith IE.

The Medical Treatment of Breast Cancer. Postgraduate Update 1993; 505-512

- 16 -

55 Van Hoef MEHM, Radford JA, Jones AL, Smith IE, Earl HM, Woll PJ, Thalder

N. Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC). Annals of Oncology 1993; 4: 877-881

56 Smith IE, Jones AL.

Second-line chemotherapy for advanced breast cancer: old drugs and new. ASCO Fall Educational Conference 1993.

57 Jones AL, Powles TJ.

Chemoprevention of Breast Cancer. Reviews on Endocrine-related Cancer 1993; 43: 33-42

58 Jones AL, Smith IE.

Navelbine and the anthrapyrazoles. Haematology/Oncology Clinics of North America 1994; 8: 141-152.

59 Jones AL, Trott P, Rosin RD, Sauven P, Glazer G, Cunningham D, Hermon-

Taylor J, Coombes RC, Stein R, Parker M, Kirkham J, Cunningham D. A pilot study of intraperitoneal cisplatin in the management of gastric cancer. Ann Oncol 1994; 5: 123-126.

60 Jones AL, Smith IE, O'Brien MER, Talbot D, Walsh G, Ramage F,

Robertshaw H, Ashley S. Phase II study of continuous infusional 5-FU with epirubicin and cisplatin (infusional ECF) in patients with metastatic and locally advanced breast cancer: an active new regimen. JCO 1994; 6: 1259-1265.

61 Powles TJ, Jones AL, Ashley SE, O'Brien MER, Tidy VA, Treleaven J,

Cosgrove D, Nash AG, Sacks N, Baum M,McKinna JA, Davey JB. Completion of accrual to the pilot Royal Marsden Hospital Tamoxifen prevention trial including bone, lipid and gynaecological toxicity. Breast Cancer Research and Treatment 1994; 31: 73-82.

62 Jones AL, Smith IE.

The Taxanes. Cancer Topics 1994; 9(12): 10-13.

63 Jones AL.

Hormonal therapy and immunotherapy for cancer. Medicine International 1995; 23:10: 430-433.

- 17 -

64 Smith IE, Walsh G, Jones A, Prendeville J, Johnston S, Gusterson B,

Ramage F, Robertshaw H, Sacks N, Ebbs S, McKinna J, Baum M. High complete remission rates with primary (neoadjuvant) infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13(2): 424-429.

65 Working Party, Management of advanced breast cancer in postmenopausal

women. Hospital Update 1995; Supplement 1-11.

66 Sands R, Boshoff C, Jones AL, Studd J.

Hormone replacement therapy after a diagnosis of breast cancer. Journal of the N. Amer. Menopause Society 1995; 2: 73-80.

67 Jones AL.

Cancer Services for women in the UK. Oncology in Practice 1995; 2: 19-21.

68 Jones AL.

Neoadjuvant chemotherapy. Editorial. J. Drug Dev Clin Practice 1995; 7: 137-139.

69 Bell CRW, Napier MP, Morgan RJ, Dick R, Jarmulowicz M and Jones AL.

Primary Non-Hodgkin's Lymphoma of the Prostate Gland: Case Report and Review of the Literature. Clinical Oncology 1995; 7: 409-410

70 Ellis PA, Talbot DC, Priest K, Jones AL and Smith IE.

Dose intensification of carboplatin and etoposide as first-line combination chemotherapy in small cell lung cancer. European Journal of Cancer 1995; 31A (11): 1888-1889.

71 Dowsett M, Jones AL, Johnston SRD, Jacobs S, Trunet P, Smith IE. I

In vivo measurement of aromatase inhibition by letrozole (cg 20267) in post menopausal patients with breast cancer. Clinical Cancer Research 1995; 1: 1511-1515.

72 O'Brian MER, Milan S, Cunningham D, Jones AL, Nicolson M, Selby P,

Hickish T, Hill M, Gore ME, Viner C. High dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkins disease - a pragmatic prognostic index. Br. J. Cancer 1996; 73: 1272-1277.

- 18 -

73 Jones AL

Breast Cancer: Incidence, therapy and research. Europa Donna News 1996; 2(1): 3-5

74 Jones AL

Gold-standard management of breast cancer. Oncology in Practice 1996; 26(3): 37-44.

75 Nicholson AG, Wotherspoon AC, Jones AL, Sheppard MN, Isaacson PG,

Corrin B Pulmonary B cell non-Hodgkin's lymphoma associated with autoimmune disorders: a clinicopathological review of six cases. Eur. Respir. J 1996; 9: 2022-2025.

76 Jones AL

Adjuvant treatment in high-risk breast cancer. Editorial. British Journal of Hospital Medicine 1996; 55(4): 156-158

77 Smith I, Jones A, Spielmann M, Namer M, Green MD, Bonneterre J, Wander

HE, Hatscheck T, Wilking N, Zalcberg J, Spiers J and Seymour L A phase II study in advanced breast cancer: ZD1694 ('Tomudex'*) a novel direct and specific thymidylate synthase inhibitor. Br. J. Cancer 1996; 74: 479-481

78 Munn SE, McGregor JM, Jones AL, Rustin MHA, Amlot P, Russell Jones K,

Whittaker S. Clinical and pathological heterogeneity in primary cutaneous T cell lymphoma: a report of three cases and a review of the literature. Br. J. Dermatol. 1996; 135: 976-981

79 Theocharous P, Lowdell MW, Jones AL and Prentice HG.

Immunocytochemical Detection of Breast Cancer Cells - a Comparison of Three Attachment Factors. J. Haematother. 1997; 6(1): 21-29

80 Theocharous P, Lowdell MW, Jones AL and Prentice HG.

Detection and characterisation of tumour cells in the peripheral blood of patients with primary breast cancer. Blood 1997; 90: 950

81 Jones A Primary Medical Therapy. Cancer Treatment Reviews 1997; 23 suppl.1: 33-41

- 19 -

82 Cwikla JB, Buscombe JR, Barlow RV, Kelleher TM, Parbhoo SP, Crow J,

Deery A, Jones AL, Hilson AJW. The effect of chemotherapy on the uptake of technetium-99m sestamibi in breast cancer. Eur. J.Nuclear Med. 1997; 24: 1175-1178.

83 Hall M, Jones AL

Reducing morbidity from insertion of chest drains - clamping may be appropriate to prevent discomfort and reduce risk of oedema. British Medical Journal 1997; 315 (7103):313 (letter)

84 Jones AL

Recent developments in the treatment of breast cancer. National Assn of Fundholding Practices Yearbook 1997.

85 Carmichael J, Jones AL and Hutchinson T

A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. Seminars in Oncology 1997; 24: 44-47

86 Leonard RC, Smith IE, Coleman RE, Malpas JS, Nicolson M, Cassidy J,

Jones AL, McIllmurray MN, Stuart NS, Woll PJ, Whitehouse JM More money is needed to care for patients with cancer. BMJ 1997; 315(7111): 811-2 87 Kroll L, Barnes J, Jones AL, Stein A.

Cancer in parents: communicating the diagnosis to children. BMJ 1998; 7135: 880

88 Doctor N, Dafnios N, Jones A, Davidson BR Primary squamous carcinoma of liver: presentation as liver abscess. Indian J Gastroenterology 1998; 17: 28-29 89 Caplin ME, Buscombe JR, Jones AL, Watkinson A, Burroughs AK Carcinoid tumour. Lancet 1998; 352: 799-805 90 Boudioni M, Jones AL, Leydon G, McPherson K Celebrity's death from cancer resulted in increased calls to CancerBACUP. BMJ 1998; 317-1016 (Letter) 91 Boudioni M, McPherson K, Mossman J, et al

An analysis of first-time enquiries to the CancerBACUP information service: variations with cancer site, demographic status and geographical location. BJC 1998; 79-138-145

- 20 -

92 Barnes J, Kroll L, Lee J, Stein A, Jones AL

Communication about parental illness with children who have learning disabilities and behavioural problems: three case studies.

Child: Care, Health Development 1998; 24: 441-456 93 Hall M, Jones AL New perspectives in the treatment of malignant melanoma Dermatology 1998; 3(1) 94 Jones A, Barrett-Lee PJ, Mason ML Hormonal therapy for cancer. Medicine 1999; 27:12: 29-32 95 Caplin ME, Mielcarek W, Buscombe JR, Jones AL, Croasdale PL,

Cooper MS, Burroughs AK, Hilson AJW Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours. Nuclear Medicine Communications 2000; 21: 97-102

96 Barnes J, Kroll L, Burke O, Lee J, Jones AL, Stein A

Qualitative interview study of communication between parents and children about maternal breast cancer. BMJ 2000; 321 (7259): 479-482 West Journal of Medicine 2000; 173(6): 385-389

97 Leydon GM, Boulton M, Moyniham C, Jones AL, Mossman J, Boudioni M, McPerson K Cancer patients' needs and information seeking behaviour: in depth interview study. BMJ 2000; 7239: 906-909

98 Russell-Jones R, Calonje E, Healy C, Doherty M, Butler P, Jones AL,

Whittaker S, Acland K Sentinel node biopsy for malignant melanoma. Staging procedures predict

outcome and identify patients needing further treatment. BMJ 2000; 18;321(7271): 1286-1287 99 White J, Howells A, Jones AL, Poole C, Lind M, Stuart N, Carmichael A multicentre phase II pilot study of epirubicin and Taxol (paclitaxel) in

patients with advanced breast cancer. Clinical Oncology 2000; 12(4): 256-259 100 Leydon GM, Boulton M, Moynihan C, Jones AL, Mossman J, Boudion M,

McPherson K Faith, hope and charity: an in-depth interview study of cancer patients’

information needs and information seeking behaviour. West Journal of Medicine 2000; 173(1): 26-31 101 Barnes J, Kroll L, Lee J, Burke O, Jones AL, Stein A

Factors predicting communication about the diagnosis of maternal breast cancer to children. Journal of Psychosomatic Research 2002; 52(4): 209-214

- 21 -

102 Cameron DA, Anderson A, Toy E, Evans TR, Le Vay JH, Kennedy I, Grieve

RJ, Perren TJ, Jones AL, Mansi J, Crown J, Leonard RC Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy

for high risk adjuvant breast cancer? British Journal of Cancer 2002; 2;87(12): 1365- 1369 103 Sidwell RU, McLaughlin JE, Jones AL, Whittaker SJ

Hodgkin Lymphoma in a patient with mycosis fungoides: molecular evidence of separate cellular origins. British Journal of Dermatology 2003; 148(4): 810-812

104 Eisman S, O’Toole EA, Jones A, Whittaker SJ Granulomatous mycosis fungoides presenting as an acquired ichthyosis. Clinical Exp Dermatology 2003; 28(2): 174-176 105 Jones AL

Combining traztuzamab (Herceptin) with hormonal therapy in breast cancer: What can be expected and why? Annals of Oncology 2003; 14:1697-1704

106 Johnston SR, Gumbrell LA, Evans TR, Coleman RE, Smith IE, Twelves CJ,

Soukop M, Rea DW, Earl HM, Howell A, Jones AL, Cann P, Powles TJ, Haynes BP, Nutley B, Grimshaw R, Jarmnan M, Halbert GW, Brampton M, Haviland J, Dowsett M, Coombes RC

A cancer research (UK) randomised phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to Tamoxifen. Cancer, Chemotherapy, Pharmacology 2004; 53(4): 341-348

107 Turner N, Amlot P, Platts A, Jones AL, Buscombe J

Long lasting response of langerhans cell histiocytosis to Yttrium -90 labelled Lanreotide. Lancet Oncology 2004; 5: 193-194

108 Jones AL Does axillary status matter? The medical oncologist’s view. Advances in Breast Cancer 2004; 1(2): 15-17 109 Jones AL, Barrett-Lee PJ, Mason MD Hormonal therapy in cancer. Medicine 2004; 32: 30-33

- 22 -

110 Ring AE, Smith IE, Jones AL, Shannon C, Galani E, Ellis PA.

Chemotherapy for breast cancer during pregnancy: 18 years experience from five London teaching hospitals. Journal of Clinical Oncology. 2004 (In press)

111 Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW,

Coleman RE, Perren T, Gallagher CJ, Quigley M, Gown J, Jones AL, Highley M, Leonard CF.

A phase III randomised trial of adriamycin and docetaxel versus adriamycin and cytophosphamide as primary medical therapy in women with breast cancer. An Anglo Celtic Cooperative Trial.

Journal of Clinical Oncology 2004 (In press). PAPERS SUBMITTED 1 Dodwall D, Steward A, Barrett P, Jones AL, Hardman J, Harnett J, Maher B,

Chan SY, Kunkler I, Vernon C, Dewar S, Houston S, Chaturvedi J, Bridgewater J, Brent M

A Phase II, dose ranging, double blind, multicentre study to determine the safety and efficacy of strontium-89 chloride (89Sr Cl2) for the palliation of painful bone metastases in breast cancer patients.

Journal of Clinical Oncology 2 Gaffan J, Herbertson K, Davies P, Dogan A, Jones AL. Bilateral peripheral T-cell lymphoma of the fallopian tubes – a case report. British Journal of Gynaecology. 2004. 3 Jones AL, Leyland Jones B. Treatment of HER-2 positive breast cancer. Seminars in Oncology 2004. BOOK CHAPTERS 1 Jones AL, Millar JL.

Growth factors in haemopoiesis. Balliere's Clinical Haematology 1989; 4: 131-137.

2 Jones AL, Millar JL.

The morbidity of chemotherapy to the bone marrow. In: The Complications of Cancer Management. (Eds: Plowman PN, McElwain TJ, Meadows AT), 1991. Butterworth Heinemann, pp 379-397.

3 Jones AL, Powles TJ.

The development of cancer chemoprevention trials. In: Ethical Problems in Cancer. (Eds: Williams CJ) John Wiley & Sons 1991. In press.

4 Powles TJ, Jones AL.

Chemoprevention of breast cancer. In: Medical Management of Breast Cancer. (Eds: Powles TJ & Smith IE. Martin Dunitz) 1991, pp 289-299.

- 23 -

5 Jones AL, Cunningham DC. The clinical care of patients receiving chemotherapy. In: Emesis in Anticancer Therapy. (Eds: PLR Andrews and G J Sanger). Chapman and Hall 1993, pp 229-242

6 Jones AL, Powles TJ.

Advanced breast cancer. In: Textbook of Clinical Oncology (Ed A Horwich) 1993. In press.

7 Jones AL, Powles TJ, Law MG.

Prospects for aromatase inhibitors as adjuvant therapy in breast cancer. In: Clinical use of aromatase inhibitors. Current data and future perspectives. (Eds Della Cuna R, Manni A, Pannitt F, Edimes, Paria) 1995

8 Jones AL, Gore ME.

Medical treatment of malignant tumours of the mouth, jaw and salivary glands. In: Management of Tumours of the Mouth, Jaw and Salivary Glands (Eds Langdon JD, Henk JM) Edward Arnold, 1995, pp 123-135.

9 Boshoff C, Jones AL.

Tumour necrosis factor in immunotherapy of cancer Wiley and Sons. In: Immunotherapy in Cancer. (Eds Gore, M and Riches P) John Wiley & Sons, 1996, pp 77-103

10 Jones AL, Ledermann JA

Autografting in Breast Cancer. In: Autologous Stem Cell Transplantation. In: Blood Disorders: Biological and Clinical Results in Malignancies. (Ed A Carella) 1997 Chapter 37, pp 377-384

11 Jones AL

Non-Curative Chemotherapy for Breast Cancer. In: Cancer: How Worthwhile is Non-Curative Treatment? (Eds M L Slevin and T Tate) 1998 Chapter 13, pp 189-198

12 Jones AL

Medical therapy of advanced disease. In: Medical Therapy of Breast Cancer (Eds Z Rayter and J Mansi 2003 Chapter 11, pp 283-288

- 24 -

BOOK 1 Napier M, Jones AL.

Side-effects of Chemotherapy: A Pocket Reference. Science Press, UK. 1995.

MISCELLANEOUS Review of the pattern of cancer services in England and Wales. Association of Cancer Physicians 1994 (member of writing committee). Patient Information Study. Final Research Report October 2001. Geraldine Leydon for Project Team.

- 25 -

- 26 -

APPENDIX 1 LECTURES TO CONFERENCES AND LEARNED SOCIETIES 1 British Association of Cancer Research, December 1987.

Effect of recombinant human interleukin-1 (IL-1) and recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) on haemopoietic tissue in vivo and in vitro.

2 European Congress Clinical Oncology, Madrid 1987.

Tumour necrosis factor: clinical and laboratory observations. 4 European Congress Clinical Oncology, London 1989.

A phase I trial of human tumour necrosis factor using consecutive daily doses. 5 Second Nordic Novantrone Symposium, Oslo 1989.

Chemotherapy of advanced breast cancer using mitomycin C, mitoxantrone and methotrexate (3M).

6 British Breast Group, Oxford 1990.

Inhibition of peripheral aromatisation by CGS 16949A in breast cancer patients: measurement in vivo by a new urinary (HPLC) method.

7 Nottingham International Breast Cancer Meeting, 1990.

1. Feasibility of tamoxifen in chemoprevention of breast cancer. 2. In vivo assessment of the non-steroidal aromatase inhibitor CGS

16949A in post-menopausal women with breast cancer. 8 British Association for Cancer Research/Association of Cancer Physicians,

Manchester 1991. 1. Carboplatin, vinblastine and methotrexate (CVM), an effective low

toxicity regimen for small cell lung cancer. 2. Zeniplatin (CL 286,558), an active new platinum analogue in advanced

non-small cell lung cancer (NSCLC): a phase II study. 9 Cancer Relief Macmillan Fund, Cambridge, August 1991.

Update on management of breast cancer. 10 International Conference on Hormones in Cancer, Amsterdam 1991.

Update of Royal Marsden Hospital tamoxifen prevention programme. 11 Occupational Lung Disease Course, National Heart & Lung Institute, April

1991. Mesothelioma: clinical and therapeutic aspects.

- 27 -

12 European Congress Clinical Oncology, Florence 1991. 1. Intermediate results of a phase II trial: sequential fractionated

administration of low dose dacarbazine (DTIC) and fotemustine in disseminated malignant melanoma.

2. Dexamethasone is as effective as ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.

Westminster and Royal Marsden course in Surgical Oncology, London 1991. Principles of chemotherapy.

13 British Association for Cancer Research/Association of Cancer Physicians,

Southampton 1992. 1. A randomised trial of high vs conventional dose carboplatin for

previously untreated ovarian cancer. 2. A randomised phase II trial of carmustine (BCNU) alone or in

combination with tumour necrosis factor alpha (TNFα) in patients with previously untreated malignant melanoma.

14 Aspects of Oncology Seminar, Royal Marsden Hospital, London 1992.

The incidence of second malignancy. 15 6th World Conference on Lung Cancer, Melbourne 1991.

A randomised trial comparing a low toxicity regimen - carboplatin, vinblastine and methotrexate, against adriamycin, cyclophosphamide and etoposide in small cell lung cancer.

16 3rd Mediterranean Meeting on Cancer, Naples 1992.

Neoadjuvant Chemotherapy of Breast Cancer. Update in Cardiopulmonary Pathology- Lung Cancer, Brompton Hospital Chemotherapy for Small Cell Lung Cancer.

17 5th Post Graduate Course on Clinical Oncology, Lisbon 1992

Medical Treatment of Breast Cancer: New Perspectives 18 Advanced Course on HRT, London 1992

HRT, Breast Disease and Cancer Prevention 19 Aromatase meeting, Bologna 1992

Prospects for Aromatase Inhibitors in adjuvant treatment of breast cancer 20 Cancer Relief Macmillan Fund Symposium, Milton Keynes 1992

Breast Cancer: Trends in Treatment 21 5th International Oncology Nursing Conference, Vienna 1992

Chemoprevention of Breast Cancer 22 Nottingham International Breast Cancer Meeting, 1992

Adjuvant aminoglutethemide for post menopausal women with primary breast cancer: analysis at 8 years

- 28 -

23 Collége de Gynecologie de Bordeaux et du Sudoest, 1993

Chemoprevention of Breast Cancer 24 Cancer. Management Today. Henley Management Centre, Oxon, January

1993. Clinical and economic factors in use of 5HT3 receptor antagonists.

25 First West of London Cancer Research Meeting, London, February 1993

Infusional chemotherapy for breast cancer 26 Oncology '93, London

Modern Effective Control of Emesis 27 British Association of Cancer Research 1993

Primary medical (neoadjuvant) chemotherapy with continuous infusional 5-FU, epirubicin and cisplatin for large operable breast cancer: a very active new regimen.

28 British Menopause Society, Glasgow 1993

Chemoprevention of Breast Cancer. 29 Nottingham International Breast Cancer Meeting 1993

Primary medical chemotherapy with continuous infusional 5-FU, epirubicin and cisplatin for large, operable breast cancer: a very active new regimen.

30 St. George's Hospital London. Primary care of breast cancer. December

1993. 31 III International Symposium on Breast, Sept 1993, Brazil

1) Molecular biology in the prognosis of breast cancer 2) Future directions in breast cancer 3) Treatment of massively involved axilla 4) Tumour markers

32 Royal College of Radiologists Breast Meeting on Mammography. Cheltenham

1993. Adjuvant and Neoadjuvant Chemotherapy.

33 European Congress Clinical Oncology, Jerusalem 1993

1) Primary medical therapy (ECF) for operable breast cancer using infusional chemotherapy.

2) Chemoprevention of breast cancer: RMH Update. 34 C.A.P.E. December 1993. Update on medical management of breast

cancer. London.

- 29 -

35 Royal College of Obstetricians and Gynaecologists February 1994.

Chemotherapy in Gynaecological Cancer. 36 Princess Margaret Hospital Swindon. The management of high risk early

breast cancer. Jan 1994. 37 British Breast Group 1994 38 Cancer Research Campaign. Southern Regions Annual Meeting. City

University London. Sept. 1994. Breast cancer. 39 Second Congress on Controversies in Oncology, Spain March 1994.

1) Neoadjuvant chemotherapy in breast cancer. 2) High dose chemotherapy in breast cancer.

40 Newcastle April 1994. Aromatase inhibitors: future developments. 41 American Society of Clinical Oncology 1994 (Dallas). Phase II study of

losoxantrone in previously treated and untreated patients with advanced breast cancer.

42 The Management of Liver Cancers: State of the Art. Royal Free Hospital.

Jan 1995. The Role of Systemic Chemotherapy. 43 Int. Congress Chemotherapy, Montreal 1995. Chemoprevention of Breast

Cancer (The British Tamoxifen trials) Ab 0008. 44 Royal Society of Medicine. Workshop. Cancer in the Elderly 1995. Health in

later life: advanced access and equity. 45 Cancer Research Campaign. Southern Regions Annual Meeeting. City

University London. Sept. 1994. Breast cancer. 46 Association of Cancer Physicians in Training. Durham. Sept 1995.

Management of ovarian cancer. 47 North Western Breast Cancer Group. Manchester March 1995.

Controversies in high risk primary breast cancer. 48 Europa Donna. Vienna 1995. Update on management of breast cancer. 49 Junior Oncology Club. London. May 1996. Training in Medical Oncology. 50 Breast Cancer 2000. Royal Society of Medicine Dec 1996.

Primary Medical Therapy. 51 North Thames Cancer Registry. Prospective Audit of Breast Cancer. 1998.

Royal Society of Medicine. Chemotherapy Update. 52 Royal Free Scintimammography Masterclass 1998. Royal College of

- 30 -

Physicians. Breast Imaging - what the oncologist wants. 1st European Breast Cancer Conference 1998.

53 5th Marianna Lordos Seminar. Cyprus Anti-Cancer Society 1998. 1) Dose intensification in breast cancer. 2) Cancer diagnosis and treatment -

challenges and future hopes. Keynote lecture. 54 Nottingham Breast Cancer Meeting September 1999.

Managing HER2 positive patients with antiHER2 therapy. 55 Chemotherapy and Pregnancy

Breast Cancer, Pregnancy, Lactation & Hormone Replacement Therapy. Dec. 1999. Royal Free Hospital, London.

56 Symposium: New Skills in Oncology. Amsterdam Feb 2000. New advances in endocrine therapy. 57 Symposium: Breast Key Advances. Royal College of Physicians. Feb 2000. 58 UK Breast Cancer Coalition.

Training Seminar: The Gold Standard in Breast Cancer Care. November 2000.

59 Key Advances in Effective Management of Breast Cancer, Royal College of

Physicians. Scientific evidence and expert clinical opinion for first line therapy in metastatic disease: sequential single agent versus combination therapy – July 2001.

60 24th Annual San Antonio Breast Cancer Symposium.

Targeted Therapy: The New Standard of Care in Breast Cancer: Case Study: Novel Therapies for Estrogen Receptor-Positive Patients. December 2001.

61 3rd European Breast Cancer Conference, Barcelona.

The Management of Breast Cancer and Pregnancy. March 2002. 62 Oncology Congress, Thessaloniki, Greece.

Herceptin – Current Use and Future Prospects. April 2002. 63 5th Meeting of the London Breast Cancer Forum. Royal College of Physicians.

Management of Early Breast Cancer: Controversies. April 2002. 64 Edgware GPs Luncheon Club.

Women’s Cancer Epidemiology. May 2002. 65 London College of Beauty Therapy.

Living with Breast Cancer. May 2002. 66 Oncology Planning Meeting. Royal College of Physicians: Debate and

Discussion. May 2002.

- 31 -

67 Ask the Expert Charity Lecture: What you always wanted to know about the latest developments in chemotherapy – What’s new in breast cancer. July 2002.

68 Challenges in Oncology, Dublin (Chair of Session 2).

New Potential – Relevant new signals, new targets. October 2002. 69 ESMO. Roche Satellite Symposium Lecture, Nice.

Herceptin Safety. October 2002. 70 London Breast Forum (Chair). November 2002. 71 European Conference on Navelbine Oral. Seville.

Navelbine in ABC: from IV to oral form. November – December 2002. 72 Key Advances in Clinical Management: Breast Cancer Conference. Royal

Society of Medicine. Breast Cancer Adjuvant Treatment – Chemo VS Endocrine. December 2002.

73 Mount Vernon Breast Cancer Network.

Pregnancy and Breast Cancer. February 2003. 74 Dublin. March 2003

Herceptin (trastuzumab): Future Horizons in Targeted Therapy. 75 RCP (Roche).

New Perspectives in Breast Cancer chemotherapy – Treatment of advanced breast cancer: what’s the best practice?

June 2003 76 Birdcage Walk (Aventis) Greater London Breast Cancer Forum (Chair).

Panel discussion: Is breast cancer a chronic disease? June 2003. 77 Breast Cancer Care Conference, Royal College of Physicians.

Into the future: Perspectives on Breast Cancer – Reflections on 30 years in Breast Cancer. July 2003.

78 Dominican Republic (Roche Latin America).

What does Herceptin offer for the future of cancer care? & The Future: Optimising Inhibition of EGFR and HER-2 Pathways. July 2003.

- 32 -

79 European Congress on Clinical Oncology, Copenhagen. 2003. Xeloda / Docetaxel Combinations. 80 Hanbury Manor (Joint Network Meeting). 2003. Metastatic Breast Cancer: Sequential versus Combination Therapy.